Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0058 | 0.736 | 1 |
Echinococcus granulosus | zinc finger protein | 0.0019 | 0.0435 | 0.0592 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0022 | 0.0947 | 0.1287 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0022 | 0.0947 | 0.1188 |
Loa Loa (eye worm) | hypothetical protein | 0.0069 | 0.9262 | 1 |
Brugia malayi | Bromodomain containing protein | 0.0037 | 0.3667 | 0.2673 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.4087 | 0.4413 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.4417 | 0.4769 |
Echinococcus multilocularis | zinc finger protein | 0.0019 | 0.0435 | 0.0592 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0058 | 0.736 | 1 |
Loa Loa (eye worm) | bromodomain containing protein | 0.0017 | 0.0106 | 0.0114 |
Schistosoma mansoni | zinc finger protein | 0.0019 | 0.0435 | 0.0546 |
Schistosoma mansoni | hypothetical protein | 0.002 | 0.0618 | 0.0774 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0035 | 0.3258 | 0.4427 |
Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.3679 | 0.3972 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0022 | 0.0947 | 0.1287 |
Schistosoma mansoni | bromodomain containing protein | 0.0062 | 0.7978 | 1 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0035 | 0.3258 | 0.4427 |
Loa Loa (eye worm) | PHD-finger family protein | 0.002 | 0.0618 | 0.0667 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (binding) | = 24 % | Inhibition of GSK3-beta assessed as [32P]gamma-ATP incorporation into substrate at 10 uM after 15 mins by gamma counting | ChEMBL. | 21807510 |
Inhibition (binding) | = 57 % | Inhibition of GSK3-beta assessed as [32P]gamma-ATP incorporation into substrate at 1 uM after 15 mins by gamma counting | ChEMBL. | 21807510 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.